About US
Contact us
-
UPDATED: New cancer drug benefit study sure to add to debate over drug pricesDrugmakers are already facing growing backlash to the perceived high prices of drugs, but a new study about the real benefits of cancer drugs is sure to add fuel to the fire. It says that follow-up st2016/12/6
-
Merck's Keytruda wins NICE backing in lung cancer with new data, discountReversing a previous denial, the U.K.'s cost watchdogs have endorsed Merck’s Keytruda for some patients with advanced lung cancer after weighing new data and a new discount. The move will affect about2016/12/5
-
Merck's Keytruda snags second FDA 'priority' tag this week, this time in Hodgkin'sMerck’s Keytruda has nabbed its second FDA priority review tag of the week—and it’s one that’ll help it gain ground on archrival Opdivo from Bristol-Myers Squibb. Thursday, the New Jersey drugmakeran2016/12/5
-
Analysts say Sanofi plant failings could pose issues for 2 expected blockbustersSanofi and Regeneron are facing a possible delay on one potentially big drug, sarilumab, after receiving a complete response letter tied to manufacturing problems at a plant in France. But Leerink ana2016/12/2
-
Pharma has 'hijacked' 21st Century Cures bill, Elizabeth Warren saysThe 21stCentury Cures Act seeks to ease the path to FDA approval for drug and device companies, but ifSen. Elizabeth Warren, D-Mass.,gets her way, the long-awaited bill could stall once again. On Nov.2016/12/2
-
Merck's Keytruda nabs FDA's 'priority' tag in microsatellite instability-high cancerMerck’s Keytruda isn’t letting rival Opdivo from Bristol-Myers Squibb soak up all the November regulatory attention. The immuno-oncology med has taken the spotlight back with apriority review tagfrom2016/12/1
-
Pfizer's Ibrance faces tough review at NICE, U.K. exec worriesMany drugmakers have voiced displeasure afterEngland’s cost watchdog gavenegative assessments for their promising but costly new meds. Now, though, Pfizer is voicing concerns about its Ibrance review2016/12/1
-
Bristol-Myers' Opdivo nabs European Hodgkin's nod, extending its lead in hematologyEarlier this month, Bristol-Myers Squibb’s Opdivo picked up a new indication in the U.S.—and now, it’s keeping the momentum going with another on the other side of the pond. On Wednesday, the New Jer2016/11/30
-
EpiPen maker Mylan, U.S. officials stiff-arm senator's call to testify on DOJ settlementU.S. lawmakers are still trying to hold Mylan accountable for its controversial EpiPen price hikes. But the company now flatly refuses to testify at a committee hearing convened by Sen. Charles Grassl2016/11/30
-
Pharma reps now need $750 marketing licenses to beat the streets in ChicagoIt’s official: To promote drugs in Chicago, you’ll need a $750 license—and some serious record-keeping skills. The Chicago City Council approved anordinancelast week that requires pharmaceutical sale2016/11/29